Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.
biomarkers
elasticity imaging techniques
hepatitis C virus
liver fibrosis
predictive value of tests
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
revised:
27
12
2023
received:
20
08
2023
accepted:
17
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
aheadofprint
Résumé
Non-invasive methods have largely replaced biopsy to identify advanced fibrosis in hepatitis C virus (HCV). Guidelines vary regarding testing strategy to balance accuracy, costs and loss to follow-up. Although individual test characteristics are well-described, data comparing the accuracy of using two tests together are limited. We calculated combined test characteristics to determine the utility of combined strategies. This study synthesizes empirical data from fibrosis staging trials and the literature to estimate test characteristics for Fibrosis-4 (FIB4), APRI or a commercial serum panel (FibroSure®), followed by transient elastography (TE) or FibroSure®. We simulated two testing strategies: (1) second test only for those with intermediate first test results (staged approach), and (2) second test for all. We summarized empiric data with multinomial distributions and used this to estimate test characteristics of each strategy on a simulated population of 10,000 individuals with 4.2% cirrhosis prevalence. Negative predictive value (NPV) for cirrhosis from a single test ranged from 98.2% (95% CB 97.6-98.8%) for FIB-4 to 99.4% (95% CB 99.0-99.8%) for TE. Using a staged approach with TE second, sensitivity for cirrhosis rose to 93.3-96.9%, NPV to 99.7-99.8%, while PPV dropped to <32%. Using TE as a second test for all minimally changed estimated test characteristics compared with the staged approach. Combining two non-invasive fibrosis tests barely improves NPV and decreases or does not change PPV compared with a single test, challenging the utility of serial testing modalities. These calculated combined test characteristics can inform best methods to identify advanced fibrosis in various populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
Pays : United States
Organisme : NIDA NIH HHS
Pays : United States
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
World Health Organization. Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics. 2022. Accessed March 1, 2023. https://www.who.int/publications-detail-redirect/9789240052734
Wester C, Hepatitis C. Virus clearance Cascade-United States, 2013-2022. MMWR Morb Mortal Wkly Rep. 2023;72:720. doi:10.15585/mmwr.mm7226a3
Bhattacharya D, Aronsohn A, Price J, Lo Re V III, the AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023;ciad319. doi:10.1093/cid/ciad319. Online ahead of print.
AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C|HCV Guidance. Accessed May 9, 2023. https://www.hcvguidelines.org/
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, clinical practice guideline panel, chair: EASL governing board representative: panel members: EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. doi:10.1016/j.jhep.2021.05.025
World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. World Health Organization. 2018. Accessed July 23, 2021. http://www.ncbi.nlm.nih.gov/books/NBK531733/
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. doi:10.1053/j.gastro.2004.11.018
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54. doi:10.1002/hep.20506
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. doi:10.1016/j.jhep.2008.02.008
Karam AR, Beland MD. Liver ultrasound Elastography: review of techniques and clinical applications. R I Med J. 2020;103(5):26-29.
Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56(1):55-62. doi:10.1016/j.jhep.2011.05.024
Coyle C, Moorman AC, Bartholomew T, et al. The Hepatitis C virus care continuum: linkage to Hepatitis C virus care and treatment among patients at an urban health network, Philadelphia. PA Hepatol Baltim Md. 2019;70(2):476-486. doi:10.1002/hep.30501
Knop V, Hofmann WP, Buggisch P, et al. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat. 2019;26(2):224-230. doi:10.1111/jvh.13021
Kelly ML, Riordan SM, Bopage R, Lloyd AR, Post JJ. Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: a multi-centre observational study. PLoS One. 2018;13(2):e0192763. doi:10.1371/journal.pone.0192763
Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022;7(4):307-317. doi:10.1016/S2468-1253(21)00397-6
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol Baltim Md. 2003;38(2):518-526. doi:10.1053/jhep.2003.50346
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol Baltim Md. 2006;43(6):1317-1325. doi:10.1002/hep.21178
Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatol Baltim Md. 2009;49(6):1821-1827. doi:10.1002/hep.22859
Castera L, Winnock M, Pambrun E, et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15(1):30-39. doi:10.1111/hiv.12082
Afdhal NH, Bacon BR, Patel K, et al. Accuracy of Fibroscan, compared with histology, in analysis of liver fibrosis in patients with Hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13(4):772-779.e3. doi:10.1016/j.cgh.2014.12.014
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807-820. doi:10.7326/0003-4819-158-11-201306040-00005
Schmid P, Bregenzer A, Huber M, et al. Progression of liver fibrosis in HIV/HCV Co-infection: a comparison between non-invasive assessment methods and liver biopsy. PLoS One. 2015;10(9):e0138838. doi:10.1371/journal.pone.0138838
Verlinden W, Bourgeois S, Gigase P, et al. Liver fibrosis evaluation using real-time shear wave elastography in hepatitis C-monoinfected and human immunodeficiency virus/hepatitis C-coinfected patients. J Ultrasound Med off J Am Inst Ultrasound Med. 2016;35(6):1299-1308. doi:10.7863/ultra.15.08066
Assoumou SA, Nolen S, Hagan L, et al. Hepatitis C Management at Federally Qualified Health Centers during the opioid epidemic: a cost-effectiveness study. Am J Med. 2020;133(11):e641-e658. doi:10.1016/j.amjmed.2020.05.029
Assoumou SA, Wang J, Nolen S, et al. HCV testing and treatment in a National Sample of US federally qualified health centers during the opioid epidemic. J Gen Intern Med. 2020;35(5):1477-1483. doi:10.1007/s11606-020-05701-9
Barocas JA, Savinkina A, Lodi S, et al. Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study. Clin Infect Dis off Publ Infect Dis Soc Am. 2021;75(1):e1112-e1119. doi:10.1093/cid/ciab779
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266. doi:10.1016/S2468-1253(19)30349-8
Driedger M, Vachon ML, Wong A, et al. Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: a CANUHC analysis. Can Liver J. 2021;4(3):283-291. doi:10.3138/canlivj-2021-0003
Ghany MG, Marks KM, Morgan TR, et al. Hepatitis C guidance 2019 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C virus infection. Hepatology. 2019;71:721. doi:10.1002/hep.31060
Crossan C, Tsochatzis EA, Longworth L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess (Winch Eng). 2015;19(9):1-409, v-vi. doi:10.3310/hta19090
Knop V, Hoppe D, Vermehren J, et al. Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study. J Viral Hepat. 2021;28(11):1604-1613. doi:10.1111/jvh.13587
Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic Hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2018;16(1):27-38.e4. doi:10.1016/j.cgh.2017.04.038
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatol Baltim Md. 2007;46(1):32-36. doi:10.1002/hep.21669
Njei B, McCarty T, Luk J, Ewelukwa O, Ditah I, Lim J. Use of transient elastography in patients with HIV-HCV coinfection: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(10):1684-1693. doi:10.1111/jgh.13337
Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci. 2011;56(10):3038-3044. doi:10.1007/s10620-011-1710-2
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. 2016. Accessed May 9, 2023. https://www.who.int/publications-detail-redirect/WHO-HIV-2016.06
Fleurence RL, Collins FS. A National Hepatitis C Elimination Program in the United States: a historic opportunity. JAMA. 2023;329(15):1251-1252. doi:10.1001/jama.2023.3692
Thompson WW, Symum H, Sandul A, et al. Vital signs: Hepatitis C treatment among insured adults - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022;71(32):1011-1017. doi:10.15585/mmwr.mm7132e1
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatol Baltim Md. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
Shrank WH, Rogstad TL, Parekh N. Waste in the US health care system: estimated costs and potential for savings. JAMA. 2019;322(15):1501-1509. doi:10.1001/jama.2019.13978